Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Use a revolutionary bone graft with success in the surface
We’re on a mission to help tackle the problem of non-unions. So we developed an advanced bone graft – with a unique submicron topography – for spinal fusions you can rely on.
CLINICAL EVIDENCE17%
of fusion procedures result in a non-union1-2
10%
of patients go on to require revision procedures3
The good news? Using the most effective bone graft can improve outcomes by up to 60%
Peer-reviewed research from spinal surgeons indicates that synthetic bone graft extenders are among the best options for posterolateral fusion.2,4
Start safeguarding your patients against non-unions by harnessing the power of osteoimmunology with MagnetOs
The science behind the surface
MagnetOs, our biphasic calcium phosphate (BCP) bone graft, mimics the porous, trabecular structure of cancellous bone. We developed its unique submicron surface topography to harness the power of macrophage polarization and osteoimmunology to deliver uniform, stable and reliable fusions.
Watch to find out how MagnetOs’ needle-shaped submicron features promote attachment and spreading of macrophages, leading to the formation of bone, even in soft tissue.5*
Preclinical data
MagnetOs vs Key competitors
In clinically-relevant animal models of spine fusion, Vitoss® BA2X and Novabone Putty appeared to be fused when assessed by X-rays. But histological exploration uncovered only fibrous tissue.7*
In contrast, MagnetOs was filled with new bone and radiographically, biomechanically and histologically equivalent to autograft, at all timepoints.7*
MagnetOs vs Autograft
In peer-reviewed preclinical studies, multiple fusion end-point analysis at the 12-week mark showed MagnetOs’ performance was equivalent to the ‘gold standard’ of autograft.6,7*
Preclinical data
Versus Competitors
Versus Autograft
What people are saying about MagnetOs
Scoliosis cases
Mr Tucker, Great Ormond St, London
Want to learn more about MagnetOs?
Book your own appointment with one of our scientific experts.
SET UP MEETINGSuggested Reading
References And Disclaimers
1. Medtech 360 report “Orthopedic Biomaterials Market Analysis 2017”.
2. Hsu WK et al., Global Spine J (2012);2:239-248.
3. Mabud T et al., Clin Spine Surg 2017;30:E1376–E1381.
4. Morris MT, et al. European Spine Journal 2018;27:1856-1867.
5. Van Dijk LA, et al. JOR Spine 2018;e1039.
6. Van Dijk LA, et al. J Biomed Mater Res B 2019 Aug;107(6):2080-2090.
7. Walsh W et al., NASS 2019 annual meeting, oral presentation; van Dijk et al. Clin Spine Surg; 2020; Feb [Epublication].
* Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans.
¥ MagnetOs is not cleared by FDA as an osteoinductive bone graft.
Please refer to the Instructions for Use for a full list of indications, contraindications, warnings, and cautions.
Kuros Biosciences B.V. or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: MagnetOs; Kuros Biosciences. Vitoss® is a registered trademark of Stryker Corp. Novabone Putty® is a registered trademark of Novabone Products LLC.